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Introduction
Pancreatic cancers are characterized by poor prognosis
and high mortality rate. Currently, in many countries,
pancreatic duct carcinoma is the fourth most common
cause of death among malignant cancer patients
(according to the National Cancer Register Centre in
the year 1999 in Poland there were approximately
3,500 deaths due to pancreatic duct carcinoma) [1].
These data indicate great importance of the analysis of
the mechanisms of invasion and metastasis of pancre-
atic cancers. The disease prognosis is determined by
the ability of cancer cells to metastasize to local lymph
nodes and distant organs [2]. Metastasis is first of all
the result of the loss of intercellular interactions, i.e.
cell adhesion. Disorders affect epithelial integrity, the
mechanism of cell-cell junctions becomes disturbed
and cancer cells may easily infiltrate adjacent tissues,
and migrate to lymphatic and blood vessels. In normal
epithelium, the adhesion molecules serving as mem-
brane receptors are responsible for intercellular inter-
actions. E-cadherin (also known as type 1 cadherin,
gene CDH1, CD324), a glycoprotein that belongs to a
family of calcium-dependent receptors, is capable of
mediating homotypic intercellular interactions. E-cad-
herin consists of the extracellular domain by which it
binds to E-cadherin on an adjacent cell, the transmem-
brane domain and the cytoplasmic domain reacting
with catenins [3]. Four types of catenins have been
identified: alpha, beta, delta and gamma. β-catenin, a
component of the cadherin-catenin complex, possesses
an armadillo repeat domain and is thus involved in
protein-protein bonds. It also functions as a component
of the Wnt signaling pathway and can be an oncogene
[4]. γ-Catenin (plakoglobin) has been identified as a
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component of desmosomes and may also bind to clas-
sical cadherins [5]. E-cadherin demonstrates specific
binding to β-catenin or γ-catenin, whereas α-catenin
binds to β-catenin or γ-catenin, but not to E-cadherin.
Thus, there are two types of complexes: 1/ the E-cad-
herin, α- and β-catenin complex and 2/ the E-cadherin,
α- and γ-catenin complex [6,7]. α-Catenin binds the cad-
herin-catenin complexes to actin filaments of the
cytoskeleton via binding to vinculin and alpha-actin pro-
teins. It has been also observed that α-catenin when not
in the complex with other catenins regulates arrange-
ment of actin filaments. In this way, the cadherin/catenin
complexes stabilize epithelial architecture [7,8].
There is a growing body of evidence indicating that
adhesion disorders have a major role in generating inva-
siveness of cancer cells. Gene CDH1 mutations correlate
with cancers of the stomach, colon, thyroid, breast and
ovaries. Increased proliferation of these cancers and
invasion of cancer cells into adjacent tissues and distant
organs are associated with E-cadherin dysfunction
[6,9,10,11]. Therefore, the aim of the current study was
immunohistochemical assessment of the expressions of
E-cadherin and α-, β- and γ-catenins in pancreatic duct
carcinoma as correlated with clinicopathological param-
eters, lymph node involvement and distant metastases. 
Materials and methods
Materials. The study was performed using archive material. The
study group included 29 patients treated surgically for pancreatic
duct carcinomas at the Department of General Surgery and Gas-
troenterology, Medical University of Bia³ystok. The control group
were 15 patients with normal pancreas. Sections, 5 µm-thick, were
cut from paraffin blocks and stained with hematoxylin and eosin
(H+E). The routine histopathological assessment of the sections
referred to the histological type (adenocarcinoma and adenocarci-
noma mucinosum), malignancy grade (G), clinicopathological
pTN status, regional lymph node involvement and the presence of
distant metastases. 
Immunohistochemistry. Immunohistochemical examination was
performed according to the following protocol. Formalin-fixed,
paraffin-embedded tissue specimens were cut on a microtome into
5 µm sections, which were then deparaffinized in xylene and
hydrated in alcohol. To expose the antigen, the slides were heated
in a microwave oven for 15 min in citric acid buffer (pH=6.0). The
activity of endogenous peroxidase was blocked by incubating the
sections in 0.5% hydrogen peroxide in methanol. Next, the samples
were incubated with monoclonal antibodies: E- cadherin (NCL-E-
Cad, Novocastra Laboratories Ltd; dilution 1:50) – for 60 min, β-
catenin (NCL-B-CAT, Novocastra Laboratories Ltd) – for 60 min;
dilution 1:100, α-cathenin (α-E-caten, Santa Cruz Biotechnology)
– overnight at 4°C, dilution 1:300 and γ-catenin (γ-catenin, Santa
Cruz Biotechnology) – overnight at 4°C, dilution 1:100. Reaction
was performed in ABC technique using Novostain Super ABC
Universal Kit (NCL-ABCm, Novocastra Laboratories Ltd.). Color
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Table 1. Correlation between the expression of E-cadherin and β-catenin proteins and clinicopathological parameters in pancreatic cancer.
*NS- no statistical significance. Relationship is significant at the level of p<0.05. Significant relationship is marked in bold.
reaction for peroxidase was done with DAB chromogen (DAKO
S3000, DAKO, Poland). 
A semiquantitative method was used to evaluate E-cadherin
and β-catenin expressions, which were defined as follows: 0 score:
no expression; 1 score: expression in cytoplasm, 2 score: decreased
expression, 3 score: expression at cell membrane. A score of 0 to 2
was defined as abnormal expression for E-cadherin and β-catenin.
The α- and β-catenin expressions were observed in the cytoplasm
and were defined as positive (reaction present in ≥50% of tumor
cells) or negative (lack of reaction or reaction present in <50% of
tumor cells).
Statistical analysis. Spearman's correlation coefficient was used
for statistical analysis. A p-value of <0.05 was considered statis-
tically significant.
Results
Expressions of E-cadherin and α-, β- and γ-
catenin proteins in normal pancreas
In normal pancreas, membrane expressions of E-cad-
herin and β-catenin were observed in the glandular
cells of the pancreas, in pancreatic duct epithelial cells
and in the islets of Langerhans. However, α-catenin
and γ-catenin proteins were localized in the cytoplasm
of these cells. Stromal expression of these glycopro-
tein and proteins was negative. 
Expressions of E-cadherin and α-, β- and γ-
catenins in pancreatic cancer cells 
In pancreatic duct carcinoma, loss in membrane E-cad-
herin expression was noted in 30% of cases (9/29), in
cytoplasmic expression in 20.7% (6/29) of cases, where-
as in 48.3% (14/29) of cases no expression was found.
Similar results were obtained for β-catenin expression,
which in pancreatic duct cancer cells was present in cell
membrane in 20.7% (6/29) of cases, in the cytoplasm in
27.6% (8/29) of cases, lack of expression being noted in
51.7% (15/29) of cases. Nuclear expression of β-catenin
was negative. The expression levels of α- and γ-catenin
proteins in the cytoplasm of cancer cells were lower as
compared to normal pancreatic cells in 30% (9/29) and
58.6% (17/29) of cases, respectively. 
The statistical analysis of the results revealed no
correlations of the protein expressions with gender and
age of patients, histological type (Hp), histological
grade (G) and the presence of local lymph node
involvement or distant metastases (Tables 1, 2). How-
ever, correlations were found between the expression
of E-cadherin and β-catenin (p<0.0001) as well of α-
catenin with β-catenin (p=0.006) and γ-catenin
(p=0.026).
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Table 2. Correlation between the expression of α-catenin, γ-catenin proteins and clinicopathological parameters in pancreatic cancer. 
NS- no statistical significance. Relationship is significant at the level of p<0.05. Significant relationship is marked in bold.
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Fig. 1. Immunohistochemical staining.Normal pancreatic tissue shows membrane reaction for E-cadherin (A) and β-catenin (B), and cyto-
plasmic reaction for α-cateninγ (C) and γ-catenin (D). Pancreatic duct carcinoma tissue shows cytoplasmic or absent reaction for E-cad-
herin (E) and β-catenin (F) and lower cytoplasmic reaction for for α-cateninγ (G) and γ-catenin (H).
Discussion
Adhesion molecules are responsible for cell-cell and
cell-intercellular environment interactions, creating
appropriate tissue architecture. E-cadherin and
catenins form functional complexes that maintain cell
adhesion. The role of adhesion proteins in neoforma-
tion involves angiogenesis, loss of tissue continuity,
lack of cell-cell contact and contact with extracellular
matrix, which promotes neoplastic spread via metasta-
sis formation. Loss of cancer cell adhesion precedes
the process of metastases. Cancer cells lose intercellu-
lar adhesion potential and are able to migrate outside
the primary tumor area to the lymphatic vessels,
metastasizing to lymph nodes or to the blood vessels to
form distant metastases. These processes have been
confirmed by other researchers who showed decreased
or negative expressions of E-cadherin and α-, β- and γ-
catenins or abnormal localization of these proteins in
cancer cells [12-15]. In our study, immunohistochemi-
cal staining revealed that E-cadherin protein lost its
functionality, showing cytoplasmic expression or a
complete lack of expression. This may be due to E-
cadherin defects, such as lack of the cytoplasmic
domain leading to loss of interaction with catenins,
lack of the extracellular domain (E-cadherin is not able
to form bonds with cadherin on an adjacent cell), gene
mutations and deletions, chromatin reorganization,
hypermethylation or loss of transcription factors [16].
Moreover, some oncogene products destabilize the
effects of the cadherin-catenin complexes. Physiologi-
cally, free catenins are phosphorylated by glycogen
synthase kinase-3β (GSK-3β) and quickly degraded.
When the Wnt pathway becomes activated, GSK-3β
protein is blocked and catenins are accumulated in
high concentration in the cytoplasm. Then, they are
transferred to the cell nucleus where they bind to the
transcription factors TCF/LEF-1, thus affecting the
expression of target genes. Some authors have
observed nuclear expression of β-catenin in pancreatic
cancer, which could indicate that carcinogenesis is also
associated with the Wnt pathway [17,18]. We observed
a distinct loss of membranous and cytoplasmic β-
catenin expression and no nuclear reaction with GSK-
3β, which could suggest that the Wnt pathway had not
been activated and free catenins had been degraded
with GSK-3 involvement. On the other hand, Zeng et
al. [19] observed activation of the Wnt/β-catenin path-
way in 65% of pancreatic cancer cases, irrespective of
mutation in β-catenin gene. They also noted an
increase in the content of GSK-3β protein in pancreat-
ic cancer cells and accumulation of E-cadherin protein
in the cytoplasm, which however did not impair the E-
cadherin/β-catenin complex.
However, it has been proved that abnormal expres-
sions of E-cadherin and α-, β- and γ-catenins are asso-
ciated with clinicopathological parameters. According
to Joo et al. [12], reduced expressions of E-cadherin
and α- and β-catenin are related to histological malig-
nancy grade. The expression levels of these proteins
are lower in low-differentiated carcinomas. Also in our
study, E-cadherin showed abnormal expression in ade-
nocarcinoma mucinosum and G3 tumors in as many as
100% of cases, although no statistical significance was
noted. Karayiannakis et al. [14] have found that the
expression of α- and β-catenin correlates with the
presence of local lymph node involvement and distant
metastases, whereas abnormal expression of β-catenin
correlates only with lymph node involvement.
Although with no statistically significant correlations,
we observed disorders in E-cadherin and β-catenin
expressions in as many as 75% of cases with distant
metastases. Moreover, other researchers have found
that the expressions of E-cadherin and α-catenin cor-
relate with survival of patients suffering from pancre-
atic duct carcinomas. Julkunen et al. [15] have also
demonstrated that the expression of all catenins (α, β,
γ) is associated with worse prognosis. Besides, Li et al.
[20] have concluded that changes in the expression of
E-cadherin and α-catenin (reduced expression and
abnormal distribution in the cell) are connected with
an early phase of pancreatic duct carcinoma, whereas
a complete loss of these proteins is associated with
advanced pancreatic cancer. Our findings showed no
correlation of the expressions of E-cadherin and α-, β-
and γ-catenin with any of the clinicopathological
parameters suggesting tumor growth.
Despite the lack of correlation between the clinico-
pathological parameters and the expressions of E-cad-
herin and α-, β- and γ-catenins, the expressions of E-
cadherin and β-catenin showed abnormal localization
in cancer cells. Moreover, a correlation was found
between disturbances in localization of E-cadherin and
β-catenin, which is consistent with observations
reported by other authors. Our findings indicate strong
correlations of E-cadherin expression disorders with
α-, β- and γ-catenins and certain tendency associa-
tions, although statistically insignificant, of the
increase in tumor aggressiveness with the loss of E-
cadherin expression and change in its localization.
However, such a small group of cases does not allow
definite conclusions. The study should be continued on
an enlarged group of patients. 
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